DE HB401

Exempts FDA-approved pharmaceutical products containing marijuana or tetrahydrocannabinols (THC) from Delaware's Schedule I controlled substances list

Applies exemption only to drugs approved by the US Food and Drug Administration, allowing them to be prescribed and dispensed like other FDA-approved medications

Modifies the definition of "marijuana" in Delaware Code to exclude products approved by the FDA

Maintains prosecution of illegal possession or sale of controlled substances under existing state law

Enables patient access to FDA-approved marijuana-containing therapies, such as cannabidiol (CBD) products for rare pediatric seizure disorders, without administrative delays pending state rescheduling